<div id="readability-page-1"><p><span>Halozyme Therapeutics (NASDAQ:HALO - Get Free Report)</span> had its target price reduced by research analysts at Morgan Stanley  from $96.00 to $93.00 in a report released on Tuesday,Benzinga reports. The brokerage currently has an &#34;overweight&#34; rating on the biopharmaceutical company's stock. Morgan Stanley's target price would suggest a potential upside of 27.85% from the company's current price.</p><div><p><span></span><span>Get <strong>Halozyme Therapeutics</strong> alerts:</span></p></div><p>A number of other research firms also recently weighed in on HALO. Wells Fargo &amp; Company increased their price target on shares of Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an &#34;equal weight&#34; rating in a research note on Thursday, February 19th. HC Wainwright increased their price target on shares of Halozyme Therapeutics from $90.00 to $95.00 and gave the stock a &#34;buy&#34; rating in a research note on Wednesday, April 29th. Wall Street Zen downgraded shares of Halozyme Therapeutics from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Saturday, February 21st. TD Cowen  reaffirmed a &#34;buy&#34; rating on shares of Halozyme Therapeutics in a research note on Wednesday, February 18th. Finally, Benchmark increased their price objective on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a &#34;buy&#34; rating in a research report on Thursday, February 19th. Six equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one  has issued  a Sell rating to the company's stock. Based on data from MarketBeat, Halozyme Therapeutics currently has an average rating of &#34;Hold&#34; and an average price target of $80.67.</p><p><b>View Our Latest Research Report on HALO</b></p><h2>Halozyme Therapeutics Stock Performance</h2><p>Halozyme Therapeutics stock traded up $6.33 during midday trading on Tuesday, hitting $72.74. 2,175,469 shares of the company's stock were exchanged, compared to its average volume of 1,740,726. Halozyme Therapeutics has a 12-month low of $47.50 and a 12-month high of $82.22. The company has a debt-to-equity ratio of 43.89, a quick ratio of 3.66 and a current ratio of 4.66. The stock has a market cap of $8.62 billion, a price-to-earnings ratio of 29.22, a price-to-earnings-growth ratio of 0.26 and a beta of 0.89. The firm's 50 day simple moving average is $65.68 and its 200 day simple moving average is $68.57. </p><p>Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, topping analysts' consensus estimates of $1.54 by $0.06. The firm had revenue of $376.71 million for the quarter, compared to the consensus estimate of $358.60 million. Halozyme Therapeutics had a net margin of 22.69% and a return on equity of 136.12%. The firm's revenue was up 42.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.11 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS.  Equities research analysts predict that  Halozyme Therapeutics will post 7.68 EPS for the current year. </p><h2>Insider Activity</h2><p>In other news, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $64.24, for a total value of $1,284,800.00. Following the completion of the transaction, the chief executive officer directly owned 767,780 shares of the company's stock, valued at approximately $49,322,187.20. The trade was a 2.54% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,625 shares of Halozyme Therapeutics stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $63.48, for a total transaction of $103,155.00. Following the completion of the transaction, the director directly owned 38,498 shares of the company's stock, valued at $2,443,853.04. This trade represents a 4.05% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 90,482 shares of company stock valued at $6,073,942. Company insiders own  2.50% of the company's stock. </p><h2>Institutional Inflows and Outflows</h2><p>Several hedge funds and other institutional investors have recently modified their holdings of HALO. Measured Wealth Private Client Group LLC boosted its stake in  Halozyme Therapeutics by 51.5% during the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 124 shares during the period.  Abel Hall LLC raised its position in shares of  Halozyme Therapeutics by 4.2% during the 4th quarter. Abel Hall LLC now owns 3,216 shares of the biopharmaceutical company's stock worth $216,000 after buying an additional 129 shares in the last quarter.  StoneX Group Inc. raised its position in shares of  Halozyme Therapeutics by 3.8% during the 4th quarter. StoneX Group Inc. now owns 3,650 shares of the biopharmaceutical company's stock worth $246,000 after buying an additional 132 shares in the last quarter.  Moran Wealth Management LLC raised its position in shares of  Halozyme Therapeutics by 0.4% during the 4th quarter. Moran Wealth Management LLC now owns 35,596 shares of the biopharmaceutical company's stock worth $2,396,000 after buying an additional 151 shares in the last quarter.  Finally, Twin Capital Management Inc. raised its position in shares of  Halozyme Therapeutics by 1.4% during the 1st quarter. Twin Capital Management Inc. now owns 11,422 shares of the biopharmaceutical company's stock worth $738,000 after buying an additional 161 shares in the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds. </p><h2>More Halozyme Therapeutics News</h2><p>Here are the key news stories impacting Halozyme Therapeutics this week:</p><ul>   <li><span>Positive Sentiment: </span>Halozyme beat first-quarter expectations on both revenue and earnings, with revenue up 42% year over year to about $377 million and EPS of $1.60 topping estimates. <i></i><span>HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE</span></li>   <li><span>Positive Sentiment: </span>The company also announced a new $1 billion share repurchase program and said it expects to buy back at least $400 million in 2026, signaling confidence in cash flow and future performance. <i></i><span>HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE</span></li>   <li><span>Neutral Sentiment: </span>Halozyme reiterated full-year 2026 guidance for revenue, adjusted EBITDA, and non-GAAP EPS, which suggests management remains confident but did not raise its outlook despite the beat. <i></i><span>HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE</span></li>   <li><span>Negative Sentiment: </span>Some third-party summaries highlighted that diluted EPS came in below certain estimates, even though revenue was strong, which may temper enthusiasm around the quarter. <i></i><span>Halozyme Therapeutics, Inc. (HALO) Q1 2026 Earnings Call Transcript</span></li> </ul><h2>Halozyme Therapeutics Company Profile</h2> (Get Free Report)<p>Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.  </p><p>The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Halozyme Therapeutics</li><li>Shake Shack Stock Gets Shaken After Earnings Miss</li><li>On Holdings Sets Up for Marathon Rally: New Highs Are Coming</li><li>The DRAM Shake-Up: Samsung Stumbles, Micron Chases $1000</li><li>MP Materials Is Quietly Building a Rare Earth Powerhouse</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SEFMTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SEFMTw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Halozyme Therapeutics Right Now?</h2><p>Before you consider Halozyme Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Halozyme Therapeutics wasn't on the list.</p><p>While Halozyme Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

HALO

LABU

SBIO

IBBQ

<p>Morgan Stanley has lowered its price target for Halozyme Therapeutics (NASDAQ:HALO) from $96.00 to $93.00 while maintaining an "overweight" rating. This new target suggests a potential upside of 27.85% from the current price. Other firms have also adjusted their ratings, with Wells Fargo raising its target to $75.00 and HC Wainwright to $95.00. Halozyme's stock recently traded at $72.74, with a market cap of $8.62 billion and a P/E ratio of 29.22. The company reported strong quarterly earnings, exceeding estimates with a revenue increase of 42.2% year-over-year.</p>

Market Beat

Halozyme Therap

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

ALPS Medical Breakthrough

Invesco Nasdaq Biotechnology ETF

Proshares Ultra Nasdaq Biotech

Morgan Stanley

Wells Fargo

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

Morgan Stanley Cuts Halozyme Therapeutics (NASDAQ:HALO) Price Target to $93.00